2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Polymeric and Lipid Nanoparticles: Which Applications in Pediatrics?

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This review aims to provide the state of the art on polymeric and lipid nanoparticles, used or suggested to approach pediatric diseases’ problems and needs, and to inspire new researches in this field. Several drugs are currently not available in formulations suitable for pediatric patients. The United States Pediatric Formulation Initiative suggested applying new technologies to pediatric drug formulations, for instance, nanotechnology. The literature analysis showed that polymeric and lipid nanoparticles have been widely studied to treat pediatric diseases, and albumin nanoparticles and liposomes are already used in clinical practice. Nevertheless, these studies are focused almost exclusively on pediatric cancer treatment. Although nanomedicine may solve many needs of pediatric diseases and medicines, the unavailability of data on pharmacokinetics, safety and efficacy of both drugs and nanoparticles in pediatric patients limits the development of new pediatric medicines based on nanoparticles. Therefore, nanomedicine applied in pediatrics remains a significant challenge in the near future.

          Related collections

          Most cited references81

          • Record: found
          • Abstract: not found
          • Article: not found
          Is Open Access

          Nanoparticles: Properties, applications and toxicities

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Liposomal Formulations in Clinical Use: An Updated Review

            Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications. These closed bilayer phospholipid vesicles have witnessed many technical advances in recent years since their first development in 1965. Delivery of therapeutics by liposomes alters their biodistribution profile, which further enhances the therapeutic index of various drugs. Extensive research is being carried out using these nano drug delivery systems in diverse areas including the delivery of anti-cancer, anti-fungal, anti-inflammatory drugs and therapeutic genes. The significant contribution of liposomes as drug delivery systems in the healthcare sector is known by many clinical products, e.g., Doxil®, Ambisome®, DepoDur™, etc. This review provides a detailed update on liposomal technologies e.g., DepoFoam™ Technology, Stealth technology, etc., the formulation aspects of clinically used products and ongoing clinical trials on liposomes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Nanoparticles in the clinic: An update

              Abstract Nanoparticle drug delivery systems have been used in the clinic since the early 1990's. Since that time, the field of nanomedicine has evolved alongside growing technological needs to improve the delivery of various therapeutics. Over these past decades, newer generations of nanoparticles have emerged that are capable of performing additional delivery functions that can enable treatment via new therapeutic modalities. In the current clinical landscape, many of these new generation nanoparticles have reached clinical trials and have been approved for various indications. In the first issue of Bioengineering & Translational Medicine in 2016, we reviewed the history, current clinical landscape, and clinical challenges of nanoparticle delivery systems. Here, we provide a 3 year update on the current clinical landscape of nanoparticle drug delivery systems and highlight newly approved nanomedicines, provide a status update on previous clinical trials, and highlight new technologies that have recently entered the clinic.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Pharmaceutics
                Pharmaceutics
                pharmaceutics
                Pharmaceutics
                MDPI
                1999-4923
                07 May 2021
                May 2021
                : 13
                : 5
                : 670
                Affiliations
                [1 ]PhD Program in Chemical Science and Technology, Department of Chemistry and Pharmacy, University of Sassari, Via Muroni 23/a, 07100 Sassari, Italy; nnietogonzale@ 123456uniss.it
                [2 ]Department of Chemistry and Pharmacy, University of Sassari, Via Muroni 23/a, 07100 Sassari, Italy; aobinu@ 123456uniss.it (A.O.); pgiunc@ 123456uniss.it (P.G.); eligav@ 123456uniss.it (E.G.)
                Author notes
                [* ]Correspondence: grassu@ 123456uniss.it ; Tel.: +39-079228735
                Author information
                https://orcid.org/0000-0001-6268-8179
                https://orcid.org/0000-0002-2471-1355
                https://orcid.org/0000-0002-0499-9419
                Article
                pharmaceutics-13-00670
                10.3390/pharmaceutics13050670
                8148525
                1e126a49-8f3d-4570-9dbe-69f8a33e6bb5
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 16 April 2021
                : 05 May 2021
                Categories
                Review

                nanomedicine,polymeric nanoparticle,lipid nanoparticle,pediatric disease,pediatric medicine

                Comments

                Comment on this article